Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics Inc is poised for positive growth due to strategic transactions that enhance its clinical updates and broaden its options, especially ahead of significant clinical readouts. The company's promising pipeline, particularly with VK2735, which offers a potential monthly dosing regimen, along with the anticipated amylin agonist IND, positions it favorably for lucrative partnerships and financing opportunities. Furthermore, Viking's advanced stage and strong data relative to its peers potentially increase its attractiveness to investors, magnifying the company's value in an increasingly competitive metabolic market.

Bears say

Viking Therapeutics Inc. faces significant challenges characteristic of the biopharmaceutical industry, including the potential for unexpected clinical trial outcomes and regulatory uncertainty that could adversely impact its development pipeline. The company is also navigating increasingly complex and price-sensitive commercial markets, which add to the risk associated with its product candidates, VK2809, VK5211, and VK0214. Additionally, the heightened scrutiny surrounding US/China licensing deals may further complicate its operational environment, introducing additional uncertainty to its financial outlook.

Viking Therapeutics (VKTX) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 10 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.